Currently, a first-class ANXA3 inhibitor has been tested in triple-negative breast cancer, the small molecule SL18, reported as ANXA3-specific, showed low toxicity and efficiency in vivo by inactivating the Wnt/β-catenin pathway.74 The gene discussed is ANXA3; the disease is triple-negative breast carcinoma.